Haemonetics (NYSE: HAE - Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability. Risk and Volatility Haemonetics has a beta of 0.36,
BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May 7, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 7, 2026.
VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval to expand the labeling for the VASCADE MVP® XL venous vascular closure system to include procedures using 10-14F inner diameter (ID) and up to 17F outer diameter (OD) procedural sheaths. With this label expansion, the VASCADE MVP XL system is approved for larger sheaths used in market-leading technologies for pulsed field ablation (PFA) and left atrial appendage closure (LAAC) to treat atrial fibrillation.
Invenomic sold 498,317 shares of Haemonetics Corporation in the fourth quarter. The quarter-end position value decreased by $24.29 million due to the sale of all the fund's shares.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HAE's NexSys PCS adoption and hospital recovery signal growth ahead, but a leveraged balance sheet and stiff competition still cloud the stock's outlook.
Elo Mutual Pension Insurance Co bought a new stake in Haemonetics Corporation (NYSE: HAE) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 17,005 shares of the medical instruments supplier's stock, valued at approximately $829,000. Several other large investors
The largest contributor was Haemonetics Corp., a medical device company focused on products related to blood collection and management. Another top contributor was Mueller Industries, Inc., an industrial corporation whose holdings manufacture vital goods for important markets. Within materials, the largest detractor during the quarter was Eagle Materials Inc., a provider of heavy construction materials and light building materials to residential and nonresidential markets.
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced details about its presentation of four posters at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI) that took place this past weekend in Philadelphia, Pennsylvania.
